Overview

Most of the indications written into the dabrafenib label are combination indications. The reason is not marketing but pathway behaviour: suppressing BRAF alone leaves the downstream cascade able to switch itself back on, so the companion MEK inhibitor is there to hold the second node shut. Understanding that logic explains why the 75 mg capsule is usually dispensed as part of a pair rather than as a stand-alone purchase.

Why Two Nodes Instead of One

BRAF signals through MEK and then ERK, and this cascade is wired with feedback. When a BRAF inhibitor suppresses the first node, tumour cells frequently restore ERK output — through relief of negative feedback, through acquired changes in the pathway, or through upstream receptor tyrosine kinase signalling. Preclinical work also showed that BRAF inhibitors can paradoxically activate MAPK signalling in cells with wild-type BRAF, a phenomenon thought to underlie some of the cutaneous proliferative events seen with single-agent BRAF blockade. Adding a MEK inhibitor downstream blunts this reactivation, and combination regimens consequently became the labelled default rather than the exception.

The practical expression of this is "vertical" inhibition: two drugs aimed at consecutive steps of one pathway, given together, at full or near-full doses of each.

What Dual Blockade Means for the 75 mg Capsule

Per FDA labeling, the adult dabrafenib dose in combination regimens is 150 mg orally twice daily, supplied as two 75 mg capsules, taken with trametinib 2 mg once daily. Both products share the same fasting requirement — at least one hour before or at least two hours after a meal — because food reduces dabrafenib absorption. The 50 mg strength exists so that dose reduction can be executed without splitting capsules.

Combination therapy also widens the monitoring list. Shared or partner-driven warnings include new primary cutaneous malignancies, haemorrhage, venous thromboembolism, cardiomyopathy requiring LVEF assessment before treatment, after one month and then every two to three months, serious febrile reactions, ocular toxicity, interstitial lung disease, hyperglycaemia and serious skin toxicity. Dabrafenib is metabolised by CYP2C8 and CYP3A4 and is itself an enzyme inducer, so concomitant warfarin and certain other substrates deserve review.

FAQ

Q: Is dabrafenib ever appropriate without the MEK inhibitor? A: Yes, in a narrower setting. FDA labeling includes a single-agent indication for unresectable or metastatic melanoma with BRAF V600E mutation; nearly all other labelled uses — NSCLC, anaplastic thyroid cancer, adjuvant melanoma, BRAF V600E solid tumours and paediatric low-grade glioma — are written for dabrafenib plus trametinib.

Q: Why does the 75 mg strength matter more than the 50 mg one for starting therapy? A: Because 150 mg twice daily is the standard adult starting dose in combination regimens and it is assembled from two 75 mg capsules. The 50 mg capsule is primarily a tool for step-down dose modification when adverse reactions require it.

Q: What monitoring is required once both drugs are running? A: Left ventricular ejection fraction should be assessed before treatment, after one month and then every two to three months. Clinicians also watch for fever, new skin lesions, visual disturbances, bleeding symptoms and unremitting rash, and review concomitant medicines for CYP2C8 and CYP3A4 interactions.